Ankleshwar

"Glenmark would like to state that its Ankleshwar plant received the EIR (establishment inspection report) yesterday.

Addressing concern raised by USFDA on Ankleshwar unit: Wockhardt

The latest USFDA warning letter to Wockhardt for its active pharmaceutical ingredient plant in Ankleshwar, Gujarat is part of the "same process” of an earlier import alert the company received from the US regulator for the same facility.

Alkem falls 5%; Ankleshwar unit gets 483 observations from USFDA

The US Food and Drug Administration (USFDA) had conducted an inspection at the company‘s API (Active Pharmaceutical Ingredient) manufacturing facility located at Ankleshwar, India from December 5 to 9, 2016.

Wockhardt up 5% as USFDA excludes Ceftriaxone from import alert

Wockhardt shares rallied nearly 5 percent intraday Tuesday after the US health regulator excluded an antibiotic drug Ceftriaxone sodium from the import alert.

Wockhardt plunges 14% on import alert; Macquarie downgrades

Macquarie has downgraded it to neutral from outperform and reduced target price to Rs 1015 versus Rs 1350 per share. It says Ankleshwar facility receiving under import alert may lead to multiples falling under pressure in the near term. However, it remains bullish on the stock for long term.

Sanofi inks pact with Suzlon for captive power plant

Drug-firm Sanofi India on Monday said it has inked a pact with Suzlon Energy for a 2.1MW windmill installation, to generate renewable power for captive consumption at its Ankleshwar manufacturing site.